Want to see AVR full AI Analyst Report?
AVR Stock Chart & Stats
$8.13
$0.04(0.49%)
At close: 4:00 PM EDT
$8.13
$0.04(0.49%)
Day’s Range― - ―
52-Week Range$3.09 - $11.06
Previous Close$8.18
Volume838.13K
Average Volume (3M)151.40K
Market Cap
$763.16M
Enterprise Value$181.20
Total Cash (Recent Filing)$283.21M
Total Debt (Recent Filing)$3.73M
Price to Earnings (P/E)―
Beta1.84
Next Earnings
Aug 17, 2026EPS Estimate
-0.21Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.00
Shares Outstanding97,342,200
10 Day Avg. Volume215,658
30 Day Avg. Volume151,395
Financial Highlights & Ratios
PEG Ratio-0.20
Price to Book (P/B)-1.27K
Price to Sales (P/S)61.50
P/FCF Ratio-1.48
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$16.00Price Target Upside96.80% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-1.08
Revenue Forecast (FY)$9.87M
Bulls Say, Bears Say
Bulls Say
Focused Aortic Valve Product StrategyA clear, specialized focus on transcatheter and surgical aortic valve replacement targets a durable, high‑value segment of structural heart disease. Persistent demand for valve therapies supports long‑term addressable market potential if clinical and regulatory progress continues.
Flexible Capital Access Via ATM ProgramAn established $250M ATM facility creates durable financing optionality to fund DurAVR development and working capital needs. This reduces near‑term liquidity cliff risk by enabling incremental capital raises without a single large offering, though it may dilute shareholders if used.
Low Reported Leverage In Latest PeriodMinimal debt in the trailing period limits interest burdens and preserves borrowing capacity, providing balance sheet flexibility to support R&D and regulatory milestones. Low leverage reduces immediate solvency risk during continued investment into product development.
Bears Say
Severe And Persistent Cash BurnVery large negative operating and free cash flows are structurally material: continued burn requires frequent external financing, constrains strategic choices, and elevates dilution and runway risk. Sustainable progress depends on closing the gap between spend and revenue.
Tiny, Shrinking Revenue BaseRevenue remains very small relative to the cost base and has declined, indicating products have not generated meaningful commercial traction. Without scalable revenue growth, the company cannot self‑fund development and remains dependent on external capital over the medium term.
Historical Balance Sheet Volatility; Past Negative EquityPrior negative equity and uneven balance sheet quality suggest episodes of material losses or recapitalization, which can impair investor confidence and complicate future financings. This legacy volatility increases long‑term cost of capital and operational risk.
Anteris Technologies Global Corp. News
AVR FAQ
What was Anteris Technologies Global Corp.’s price range in the past 12 months?
Anteris Technologies Global Corp. lowest stock price was $3.08 and its highest was $11.05 in the past 12 months.
What is Anteris Technologies Global Corp.’s market cap?
Anteris Technologies Global Corp.’s market cap is $763.16M.
When is Anteris Technologies Global Corp.’s upcoming earnings report date?
Anteris Technologies Global Corp.’s upcoming earnings report date is Aug 17, 2026 which is in 13 days.
How were Anteris Technologies Global Corp.’s earnings last quarter?
Anteris Technologies Global Corp. released its earnings results on May 12, 2026. The company reported -$0.28 earnings per share for the quarter, missing the consensus estimate of -$0.271 by -$0.009.
Is Anteris Technologies Global Corp. overvalued?
According to Wall Street analysts Anteris Technologies Global Corp.’s price is currently Undervalued.
Does Anteris Technologies Global Corp. pay dividends?
Anteris Technologies Global Corp. does not currently pay dividends.
What is Anteris Technologies Global Corp.’s EPS estimate?
Anteris Technologies Global Corp.’s EPS estimate is -0.21.
How many shares outstanding does Anteris Technologies Global Corp. have?
Anteris Technologies Global Corp. has 97,342,200 shares outstanding.
What happened to Anteris Technologies Global Corp.’s price movement after its last earnings report?
Anteris Technologies Global Corp. reported an EPS of -$0.28 in its last earnings report, missing expectations of -$0.271. Following the earnings report the stock price went down -2.537%.
Which hedge fund is a major shareholder of Anteris Technologies Global Corp.?
Currently, no hedge funds are holding shares in AVR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Anteris Technologies Global Corp. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$16.00 (96.80% Upside)
$16.00 (96.80% Upside)
Hedge Fund Trend
Increased
By 5.4M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $13.8M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.0%
Last 30 Days ▲ 16.7%
Last 30 Days ▲ 16.7%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-14.53%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
401.30%
Trailing 12-Months
Company Description
Anteris Technologies Global Corp.
Anteris Technologies Global Corp. is a structural heart innovator dedicated to discovering, developing, and bringing to market medical devices that enhance the well-being of patients grappling with aortic stenosis. The company's premier offering is the DurAVR transcatheter heart valve system, a pioneering transcatheter aortic valve engineered to treat aortic stenosis by precisely emulating the performance of a healthy human aortic valve. Beyond this, Anteris develops ADAPT anti-calcification tissue, a unique preparation that transforms xenograft tissue into robust bioscaffolds. These bioscaffolds are designed to simulate human tissue for various surgical repairs, notably in aortic valve replacement. Additionally, the ComASUR delivery system, a physician-designed balloon-expandable apparatus, features a reinforced, steerable catheter. This allows for highly accurate navigation through cardiac anatomy in a controlled manner, thereby mitigating potential damage to the aorta. Founded in 1999, Anteris Technologies Global Corp. operates out of Toowong, Australia.
AVR Stock 12 Month Forecast
Average Price Target
$16.00
▲(96.80% Upside)
Technical Analysis
Anika Therapeutics
―
Apyx Medical
―
Inogen
―
Treace Medical Concepts
―
Rapid Micro Biosystems
―
Ownership Overview
7.30% Insiders
6.44% Mutual Funds
0.72% Other Institutional Investors
79.67% Public Companies and
Individual Investors











